Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2002 · The Lancet · 4,137 citations
https://doi.org/10.1016/s0140-6736(02)08512-4
B
Brian G. Feagan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.3K
Papers
89.7K
Citations
136
h-index
516
i10-index
Brian G. Feagan is an academic researcher from Western University. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Eosinophilic Esophagitis. The author has an h-index of 136, co-authored 1073 publications.
ORCID: 0000-0002-6914-3822Papers by this author
worksInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 · New England Journal of Medicine · 3,852 citations
https://doi.org/10.1056/nejmoa050516
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 · New England Journal of Medicine · 2,779 citations
https://doi.org/10.1056/nejmoa1215734
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 · New England Journal of Medicine · 2,658 citations
https://doi.org/10.1056/nejmoa1215739
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
2004 · New England Journal of Medicine · 2,202 citations
https://doi.org/10.1056/nejmoa030815
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
2015 · The American Journal of Gastroenterology · 1,784 citations
https://doi.org/10.1038/ajg.2015.233
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat